Having already created substantial value across its two main programs - KappaMab™ and KMCAR™, HaemaLogiX is progresing plans for a potential ASX listing and capital raising to further fund its operations.

The company’s lead asset, KappaMab™, has completed Phase 1, 2a, and 2b studies, demonstrating remarkable safety and compelling efficacy in patients. A higher-dose Phase 2b study is fully designed and ready for funding, providing a clear near-term clinical catalyst.

In parallel, the KMCAR™ Phase 1 trial is fully funded by Peter Mac Centre of Excellence in Cellular Immunotherapy through Federal Government and Foundation grants - effectively two trials for the price of one - reflecting strong external confidence in the science.

HaemaLogiX's IP is well-protected, with 10 patent families (40+ patents granted) extending protection to 2040 and beyond. All GMP products are manufactured and ready for first patient dosing, with CMC packages capable of scaling to future trials and commercialisation. Clinical trial designs were developed with US expert physicians, ensuring global relevance and FDA alignment.

With multiple upcoming readouts and major inflection points, HaemaLogiX is well positioned to deliver meaningful value to investors.

Atmo is unique as the only Australian-based company that provides direct exposure via an FDA cleared and reimbursed product to the largest and fastest growing therapeutic category in the world, GLP-1's and the anti-obesity medication market. This is already a US$70bn market, forecast to grow to over US$100bn in the next couple of years.

The Series B round of $25M will allow Atmo to reach breakeven within 3 years. Atmo offers the prospect of a liquidity event such as an IPO or trade sale, including possible strategic acquisition by a range of medical device players and endoscopy portfolio companies such as Medtronic, Olympus, Laborie, or Pentax, or potentially pharma companies and others in the GLP-1 space.

Alterity Therapeutics is a late clinical-stage biotechnology company developing disease-modifying therapies for neurodegenerative diseases. Its lead candidate, ATH434, is an oral small molecule designed to restore brain iron balance and inhibit the pathological protein aggregation that contributes to neuronal degeneration.

The company has completed a Phase 2 clinical trial in Multiple System Atrophy (MSA), a rare and rapidly progressive Parkinsonian disorder with no approved disease-modifying treatments. Results demonstrated target engagement, encouraging signals of clinical benefit, and a favourable safety and tolerability profile.

ATH434 has received U.S. FDA Fast Track designation and Orphan Drug designation for MSA, as well as Orphan Drug designation in Europe, providing important regulatory incentives including potential development support and market exclusivity.

Alterity’s strategy is to advance ATH434 into late-stage clinical development while continuing to build awareness of MSA and its significant unmet medical need. With promising clinical data, a differentiated therapeutic approach, and a clear development pathway, Alterity is working toward delivering the first disease-modifying therapy for MSA and creating meaningful value for patients and shareholders.

Wavewise is open to investment discussions and welcomes interest from investors who would like to explore the opportunity further.

The Drua Foundation offers partners and funders a high-trust, high-visibility vehicle for achieving measurable social outcomes at scale. Funding supports the expansion of youth outreach and health and education initiatives, strengthening resilience, aspiration and wellbeing among young people and communities across Fiji.
While philanthropic in nature, the opportunity aligns strongly with ESG, CSR and Pacific engagement priorities, delivering clear social return through nationally recognised pathways that connect sport, education and community development.

he model has been developed and piloted in New Zealand, where it has established a homeownership pipeline exceeding NZ$3 billion.

Through an equity-based home subscription approach, the platform connects capital directly to residential assets, enabling households to progressively build equity without reliance on traditional debt structures.

The platform aligns capital, developers, and community housing associations to facilitate both housing supply and access to ownership.

This alignment supports the delivery of:

• residential income streams
• participation in property value growth
• shared-equity outcomes linked to occupiers

BLOXX is currently focused on deployment in New Zealand and expansion into the United Kingdom. The platform has been designed to support future expansion into additional jurisdictions, like Australia.

Developed over three years with founder capital, BLOXX has established the operational and structural foundations required to support institutional participation in residential assets at scale.

BLOXX are not asking their investors to fund housing. BLOXX is offering a new home for your capital to enable thousands of people locked in renting to become homeowners.

Wave Hill is being structured as a blended finance opportunity, combining equity investment and philanthropic-aligned capital to support both production and the project’s broader impact strategy. This approach is designed to reduce overall investor risk while enabling the film to maximise both commercial performance and social value.

Investors are being offered access to a major Australian feature film asset with revenue potential through standard screen distribution channels. At the same time the project has clear cultural significance and powerful reputational value through alignment. The financing structure is intended to leverage government incentives and mission-aligned philanthropic and equity capital, improving the overall investment profile while supporting a robust pathway to market.

Beyond financial return potential, Wave Hill is designed to generate measurable impact through cultural recognition, First Nations participation, economic pathways and community engagement. Investors therefore have the opportunity to participate in a project that combines commercial upside with meaningful public value, and to align their capital with a landmark screen work capable of creating long-tail cultural, social and economic benefits.

The Emerging Asia Sustainable Infrastructure Fund (ESIF) offers investors access to high‑growth, climate‑aligned infrastructure across one of the world’s most dynamic regions, targeting a 16–18% gross IRR while delivering measurable environmental and social impact.
Backed by a long‑standing PATRIZIA–Mitsui strategic partnership, the fund benefits from unrivalled market access through APAC’s largest infrastructure network, with more than 15,000 staff across 67 offices enabling proprietary deal flow and deeply informed local execution.
ESIF invests in scalable mid‑market platforms across renewable energy, water, mobility, digital and social infrastructure, with a focus on greenfield opportunities.
With 100% of investments promoting environmental or social objectives, the fund directly supports the transition to low‑carbon, climate‑resilient systems across Emerging Asia, and its seed portfolio—including solar, cooling‑as‑a‑service and sustainable mobility platforms—already demonstrates strong momentum with projected returns above target.
Benefiting from PATRIZIA’s 27‑year APAC track record, a governance framework developed with cornerstone investor, the European Investment Bank, and a highly aligned investment team, ESIF presents a compelling opportunity to achieve attractive returns alongside scalable, long‑term climate impact.

The strategy targets control and significant minority investments in mid-market companies enabling the low-carbon transition in Indonesia. Key sectors include renewable energy, waste management and circular economy, transportation and logistics, and resource efficiency solutions.

The fund seeks to partner with high-quality management teams to scale businesses through operational improvements, strategic expansion, and institutionalisation. Affirma Capital’s regional platform, deep local networks, and longstanding presence in Indonesia provide strong sourcing advantages and execution capabilities.

Investors benefit from exposure to a high-growth region with increasing policy support and capital flows toward climate solutions. The strategy is designed to deliver attractive risk-adjusted returns through disciplined entry valuations, active asset management, and multiple exit pathways.

In addition to financial returns, the fund will generate measurable climate outcomes, including emissions reduction, improved resource efficiency, and enhanced climate resilience, aligning with global sustainability objectives and LP impact mandates.

Good Return provides investors with a pathway to unlock inclusive economic growth by strengthening the financial systems that serve excluded communities. Rather than financing enterprises in isolation, the fund works through local financial institutions, pairing catalytic capital with technical assistance to drive long-term systems change.
Investor capital expands access to finance for MSMEs while building institutional capability and resilience. The blended structure reduces risk while delivering strong impact additionality, evidenced through enterprise growth, improved financial access and strengthened local lenders. For investors seeking scalable, evidence-based impact within a robust Australian-regulated structure, Good Return offers a compelling mechanism to crowd capital into markets traditional finance underserves.

With over 20 years of operating history and more than USD 340 million disbursed to women-led microenterprises, SPBD provides a credible, institutionally familiar entry point into financial inclusion across multiple Pacific markets.
Financial exclusion remains a structural constraint across Pacific Island economies, particularly for women-led microenterprises. SPBD, for more than two decades, has demonstrated that unsecured lending to low-income women can be both financially sustainable and deeply transformative, enabling livelihoods, asset-building and long-term household resilience.
The proposed debt raise will directly expand access to finance for women entrepreneurs across existing Pacific markets, support entry into Kiribati, and deepen reach into underserved provinces. Investor capital translates rapidly into measurable outcomes—business creation, income stability and education support—within a mature institution combining strong repayment performance, disciplined governance and deep regional trust. SPBD presents a rare opportunity to scale impact at pace through a de-risked, well-established microfinance model.

TechCoop sits between Vietnam/SEA based aggregators/producers and global institutional buyers. Its function is to aggregate fragmented supply, verify quality and compliance, arrange logistics, and bridge payment timing. Without this intermediary layer, buyers face unreliable delivery and suppliers lack access to trade credit.

Every transaction is back-to-back: TechCoop does not purchase goods until a confirmed buyer order exists. Fees are flat and volume-based, not spread-dependent. This removes commodity price exposure from the P&L and makes margin per transaction predictable.

The Series B proceeds are allocated across three areas: (1) increasing capital to grow the VN supplier base; (2) invest in new sourcing hubs across Southeast Asia; and (3) opportunistic investments in new markets.

Current banking relationships include HSBC, Standard Chartered, BIDV, and MB Bank. Equity investors include FMO, BlueOrchard, SMBC Asia Rising Fund, TNB Aura, and AppWorks. The company is incorporated in Singapore and operates primarily through its Vietnam entity.

FireTracking addresses the accelerating climate risks faced by communities, ecosystems and critical infrastructure across Australia and the Pacific. Early detection significantly reduces disaster impacts by enabling faster response and limiting environmental, human and economic losses. The company has already deployed operational systems monitoring more than 1 million hectares, demonstrating its ability to scale across large territories. Investment will support the transition from pilot deployments to large-scale commercial rollouts in climate-vulnerable regions. FireTracking’s AI platform and scalable camera infrastructure enable cost-efficient territorial monitoring while creating a strong opportunity in a growing AUD 8B global market for early warning and risk detection technologies.

Waste Recyclers Fiji offers an opportunity to support long-standing, locally embedded circular economy infrastructure addressing one of the Pacific’s most visible environmental challenges. Capital will fund upgrades to collection and processing infrastructure, increasing efficiency and diversion rates, while expanding school and community programs that embed long-term behavioural change.
For impact investors, this opportunity delivers tangible environmental outcomes, strong local legitimacy and alignment with emerging plastic credit and blended-finance mechanisms, supporting durable impact in a small-island context.

The Fund targets net returns of 15%+ per annum by investing in Biodiversity Offset Credits issued under the New South Wales Government’s Biodiversity Offset Scheme, and is seeking to raise up to AUD 70 million.

The strategy focuses on acquiring specific Biodiversity Credits expected to experience strong demand from renewable energy developments within the New South Wales Government’s designated Renewable Energy Zones.

Established in 2008, the NSW Biodiversity Offset Scheme is one of the world’s first government-regulated biodiversity compliance markets. It requires developers to purchase offset credits to compensate for biodiversity impacts resulting from land clearing. The market has matured into an active compliance market with annual transactions of approximately AUD 200 million.

Skjander believes a significant increase in demand for Biodiversity Credits will emerge over the coming decade as large-scale renewable energy projects are delivered across NSW. We estimate this incremental demand could exceed AUD 500 million over the next ten years.

The Fund will leverage specialist expertise to identify locations where supply is constrained and future demand is expected. By acquiring credits at attractive prices early and supporting the creation of new credits, the Fund aims to capture value as compliance demand accelerates and to catalyse the market.

The GDI Fund invests in 80-120 global companies contributing to real-world decarbonisation across alternative energy, electrification, industrial decarbonisation, and energy efficiency.

The Fund targets outperformance of the MSCI World Index by 2.5% p.a. over rolling seven-year periods. Its impact objective is to grow portfolio avoided emissions over time.

GDI integrates the expertise of Nordea, UBS, UBP, Redwheel and Fulcrum within a single portfolio. Through our proprietary Multi-Manager Enhanced Portfolio (MEP) framework, we combine and optimise the underlying holdings across three dimensions: expected return, tracking risk and climate mitigation impact. The strategy also targets 0.3% p.a. outperformance relative to the underlying multi-manager model.

MEP is designed to build portfolios that are better than the sum of their parts – without adding organisational complexity. Investors benefit from one strategy, one portfolio and one aligned reporting framework.

The framework is customisable for separately managed accounts, enabling flexibility between return-first and impact-first mandates.

The GDI Fund will launch as an Australian Unit Trust in Q4 FY 2026.

Impact Alpha Partners Pty Ltd ABN 39 669 616 460 is a Corporate Authorised Representative (CAR No. 1319178) of Navigate Funds Management Pty Limited ABN 78 117 674 923, AFSL 299940 (‘Navigate’) and provides general advice only.

Delorean Corporation Ltd (ASX:DEL) is offering an investment opportunity in its next phase of near-term bioenergy projects to accelerate development and construction. Beyond its SA1 renewable gas-to-mains facility now in construction, the focus includes shovel-ready VIC1 Stanhope, NSW1 Horsley Park and QLD1 projects, supported by government grants, strategic partnerships, and long-term offtake agreements, as part of a broader $200M+ build-own-operate renewable gas portfolio.

The investment provides exposure to $200M+ build-own-operate (BOO) renewable gas portfolio with predictable, contracted revenue streams once operational. Investors gain access to high-margin assets underpinned by long-term offtake contracts, attractive project-level IRRs, and a unique ASX-listed opportunity in the rapidly growing bioenergy sector.

The projects benefit from strong industry tailwinds driven by increasing demand for renewable energy, organic waste diversion, and national decarbonisation initiatives. Biomethane produced from organic waste enables a “green” premium amid significant market undersupply, while Delorean’s experience and strategic partnerships with Tier 1 companies and government support reduce execution risk and accelerate returns.

This investment opportunity offers both financial upside and measurable environmental impact through scalable renewable energy infrastructure that supports Australia’s transition to a low-carbon economy.

Megawatt Solutions, Inc. (MSI) provides investors with a strategic entry into the Philippines’ rapidly expanding battery energy storage market, driven by renewable growth, grid congestion, and persistent ancillary service shortfalls.
MSI has executed definitive agreements with Sembcorp Industries for a 40MW/40MWh stand-alone BESS facility, with estimated project costs of USD 20–30 million and a target Commercial Operation Date of December 2026. This anchor asset demonstrates MSI’s execution capability and commercial bankability.
In addition, MSI secured a 72MW Integrated Renewable Energy with Energy Storage Systems (IRESS) project under the Philippines’ Green Energy Auction Program (GEAP), providing long-term contracted revenue visibility supported by national energy policy.
Beyond these assets, MSI is advancing 10 strategically located BESS projects across Luzon and the Visayas, positioned near NGCP substations to capture revenues from ASPA, reserve markets, and bilateral arrangements.
MSI benefits from SunAsia Energy’s institutional platform, backed by a 4.3GW renewable pipeline and award-winning leadership under President Maria Theresa “Tetchi” Capellan. SunAsia is jointly developing a 1.3GW floating solar project with Macquarie Capital, reinforcing institutional credibility and execution strength.
MSI offers investors strategic ownership in a scalable, first-mover storage platform at the center of the Philippines’ energy transition.

Ternakin is a venture-backed aquaculture company scaling fish production and processing across Indonesia. The company is supported by private investors and financial institutions and works with smallholder farmers, feed suppliers, and processors to build a more efficient and inclusive aquaculture value chain.

The proposed USD 1 million investment will fund farm expansion, processing capacity, and working capital to scale transactions across the ecosystem. By integrating smallholder farmers into structured supply chains, Ternakin improves productivity, stabilizes farmer income, and expands market access.

As the platform grows, the model delivers both financial returns and measurable impact: higher earnings for farmers, new rural jobs—particularly for women in fish processing—and reduced waste through circular use of fish by-products. This creates a scalable pathway for inclusive and sustainable aquaculture growth in Indonesia.

Freshwater scarcity is accelerating worldwide, including Australia. According to the Australian Productivity Commission, “the nation must enter a desalination building boom to avoid climate-driven economic damage that could exceed $700 billion by the end of the century” (The Age, 29 December 2025). Building resilient, affordable water supply is no longer optional, it is a socioeconomic imperative.

Azura intends to produce freshwater at sea, transforming their proven ocean energy technology into an at-sea desalination system. Using a unique Reference Site approach, Azura will validate performance and cost data for customers, generating return on investment through value creation. This is a commercial approach, not R&D.

Governance of the Reference Site is via a specialized at-sea desalination Trust:

1. The Trust’s valuation increases as technical and commercial risks are mitigated, assets are scaled, and the customer base grows.
2. The Reference Site is the means to secure a pipeline of future projects, not just one-off returns.
3. Scaling and ROI are generated through direct sales, joint ventures, licensing, or EPC-project deployment, adapting to global market conditions.

The Green Finance Centre operates at the system level of Papua New Guinea’s climate transition, catalysing capital flows into green and climate-resilient infrastructure. By enabling financial institutions to integrate green lending into mainstream operations, the Centre addresses structural barriers to climate finance mobilisation.
Engagement with investors supports the scaling of climate-positive lending facilities and the maturation of a national project pipeline spanning energy, transport, agriculture and infrastructure. With strong policy alignment and early multilateral support, the Centre offers a pathway to economy-wide impact through blended structures designed to crowd in private capital alongside public and concessional finance.

Dirty Clean Food Pty Ltd (DCF) is raising $2MM to scale Australia’s leading regenerative food brand. A champion of family farms and regenerative agriculture, DCF has reshaped how consumers in Perth access, think about, and purchase food, with inspiring results.

Since introducing regenerative agriculture in Perth in 2019 as an evolution of the organic grocery category, DCF has grown rapidly by creating a brand forged on real food, delicious food, and consumer trust.

We solve a key problem: how can we make it easy to buy local, ethical food you can trust is curbing the negative impact of industrial food on our planet?

Since then, DCF has generated $50MM+ in cumulative revenues, selling 1MM+ regeneratively grown products to 80,000 customers by home delivery, grocery and in top restaurants.

DCF has proven it can challenge “big food” by creating and leading networks of passionate, small communities. We link conscious consumers with regen farmers to build demand for healthier food and a better planet. Our partner network includes 25 regenerative farms supporting 30,000 hectares under regeneration, and 100,000 trees in our carbon insetting program.

DCF became a private company in early 2024 and is majority owned by its team, farmers, and customers. In 2025, we delivered record results. Revenue grew to $12MM+, gross margins expanded by 10 percentage points, and we successfully launched new high margin, value-added product lines including healthy family meals and pet food, paving the way for future margin expansion.

Use of Funds will support supply security needed for growth, scaling new products into grocery, sales and marketing and working capital.

Website

Myopharm’s lead asset TriGlytza® represents a uniquely compelling investment opportunity.

Current Type 2 diabetes therapies fail to adequately address the core drivers of disease progression — inflammation, metabolic dysfunction, and loss of beta cell function.

TriGlytza® is designed specifically to target upstream mechanisms through an oral, triple fixed-dose combination. By integrating anti-inflammatory, renin–angiotensin, and metabolic pathways, TriGlytza® has the potential not just to lower glucose, but modify disease progression, with potential for improved efficacy, simplified treatment and better patient adherence and compliance versus current standard of care.

From a commercial perspective, the market rewards therapies that deliver superior outcomes and simplicity of use, as demonstrated by the rapid uptake of GLP-1s, SGLT2 inhibitors, and fixed-dose combinations. There is strong precedent for high value transactions that validate FDCs as a proven strategy for product differentiation, lifecycle extension and accelerated development pathways. TriGlytza® is also positioned with the potential for combination with other T2DM drug classes, including GLP-1s (which we plan to investigate in preclinical studies over the coming months).

In summary, TriGlytza® has the potential to generate substantial value for patients, partners, and investors.

Kali Healthcare is developing an AI-powered wearable device and digital health platform to transform pregnancy monitoring, addressing a critical gap in maternal-fetal care. Globally, pregnancy complications are rising, while current monitoring technology has seen limited innovation in decades and is still largely confined to hospital settings.

Our system comprises a small wearable sensor worn on the abdomen, paired with a smartphone app and cloud-based clinician portal. Proprietary AI algorithms convert the wearable data into fetal and maternal heart rates that clinicians can interpret, enabling virtual monitoring during telehealth consultations and reducing the need for frequent hospital visits.

For clinicians, the technology offers improved reliability over traditional ultrasound-based monitoring, with sensors that monitor the fetal heart rate even when the mother or baby moves. For patients, it means greater comfort and mobility, with the potential for home-based monitoring, particularly benefiting women in rural and remote communities.

Led by a PhD-qualified founding team with deep expertise in obstetrics and medical device development, Kali Healthcare holds granted patents in Australia and the United States and has established clinical and commercial partnerships to validate its technology.

The current $2.5M AUD Seed round will fund activities to secure regulatory clearance and strengthen commercial partnerships for market launch.

ELLIS Medical Solutions is at the forefront of next-generation airway management technology, addressing a critical and under-served market in clinical care settings. Globally, airway procedures are performed ~100 million times annually yet severe complications occur in over 30% of intubations, resulting in preventable morbidity, mortality, and significant healthcare costs. This represents a high-value, high-impact opportunity for scalable medical technology. ELLIS has built a world-class team of internationally recognised respiratory specialists, medical device technology experts, and top regulatory advisors to ensure the company is uniquely positioned to navigate the complex clinical, regulatory, and commercial pathways required for market entry. The current funding round will enable ELLIS to advance product development, generate pre-clinical evidence through animal studies, and expand its technical team to ensure the company can execute its strategic milestones efficiently and maintain momentum toward market entry. For investors, ELLIS represents a rare opportunity to participate in a clinically validated, high-growth medtech solution addressing a pressing healthcare challenge. The combination of significant commercial potential, measurable impact on patient safety, and a team with deep domain expertise positions ELLIS as a compelling investment for those seeking both financial returns and meaningful contribution to global health.

Imunexus is a biotechnology company advancing a scalable multispecific biologics platform, called the imunexin™ platform, can generate novel therapies that address the root causes of complex diseases. Its dual-track strategy combines in-house drug development with platform licensing, enabling clinical value creation, strategic management of intellectual property and capital-efficient growth through partnerships and licencing.

The sector has consistently demonstrated high value transactions with big pharma at pre-clinical and phase.

The Company’s lead asset, IMX39, targets multiple sclerosis (MS), a ~$27 billion market with significant unmet need. Unlike existing therapies that primarily suppress immune activity, IMX39 is designed to intervene upstream at the source of pathogenic inflammation. In preclinical models of severe MS, IMX39 demonstrated approximately 70% reduction in disease severity, ~80% survival (versus 0% in controls), and evidence of remyelination - highlighting potential not only to control disease but also to support neurological repair. The proposed ASX listing is designed to fund the IMX39 Phase 1 clinical trial.

Beyond IMX39, the imunexin™ platform is generating additional assets and collaboration opportunities. Imunexus is progressing a pipeline across oncology and rare diseases, while pursuing partnerships to enhance third-party biologics. Strategic collaborations are in place with Mesoblast Ltd and the Baker Heart and Diabetes Institute.

This model positions Imunexus to deliver both commercial returns and meaningful patient impact through innovative therapies.

Website

Website